Ho Jin Kim, Orhan Aktas, Kristina R Patterson, Schaun Korff, Amy Kunchok, Jeffrey L Bennett, Brian G Weinshenker, Friedemann Paul, Hans-Peter Hartung, Daniel Cimbora, Michael A Smith, Nanette Mittereder, William A Rees, Dewei She, Bruce A C Cree.
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
Ann Clin Transl Neurol. 2023 Dec;10(12):2413-2420. doi: 10.1002/acn3.51911. Epub 2023 Oct 7. PubMed ID: 37804003
Further Information: